{"organizations": [], "uuid": "9a8d27b0c8206e0136eeb098b062e9ff8c612837", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/aimmune-study/aimmunes-peanut-allergy-drug-meets-main-goal-of-key-study-idUSL4N1QA2SK", "country": "US", "domain_rank": 408, "title": "Aimmune's peanut allergy drug meets main goal of key study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.005, "site_type": "news", "published": "2018-02-20T20:08:00.000+02:00", "replies_count": 0, "uuid": "9a8d27b0c8206e0136eeb098b062e9ff8c612837"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/aimmune-study/aimmunes-peanut-allergy-drug-meets-main-goal-of-key-study-idUSL4N1QA2SK", "ord_in_thread": 0, "title": "Aimmune's peanut allergy drug meets main goal of key study", "locations": [], "entities": {"persons": [{"name": "aimmune", "sentiment": "negative"}, {"name": "ankur banerjee", "sentiment": "none"}, {"name": "shounak dasgupta", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "aimmune therapeutics inc", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study.\nAimmune plans to submit the oral drug, AR101, for U.S. Food and Drug Administration review by the end of 2018, the company said.\nPeanut allergy is the leading cause of death from food-induced allergic reactions in the United States. (Reporting by Ankur Banerjee in Bengaluru; Editing by Shounak Dasgupta)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T20:08:00.000+02:00", "crawled": "2018-02-21T21:18:02.000+02:00", "highlightTitle": ""}